This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fung-Tomc, J. C. Articles by Bonner, D. P. Search for Related Content PubMed PubMed Citation Articles by Fung-Tomc, J. C. Articles by Bonner, D. P.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, 02 1995, 386-393, Vol 39, No. 2
Copyright © 1995 by the American Society for Microbiology. All rights reserved.

Activity of carbapenem BMS-181139 against Pseudomonas aeruginosa is not dependent on porin protein D2

JC Fung-Tomc, E Gradelski, B Kolek, B Minassian, M Pucci, RE Kessler and DP Bonner
Department of Microbiology, Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, Connecticut 06492, USA.

The broad antipseudomonal spectrum of the carbapenem BMS-181139 includes clinical strains and laboratory mutants of Pseudomonas aeruginosa that are resistant to imipenem. Unlike other known carbapenems (meropenem, panipenem, biapenem, and BO-2727), which have reduced activity against imipenem-resistant strains of P. aeruginosa, BMS-181139 was equally active against imipenem-susceptible (D2- sufficient) and imipenem-resistant (D2-deficient) strains. Conversely, imipenem and meropenem activities were the same against the susceptible parental strains and their BMS-181139-resistant mutants. Whereas basic amino acids antagonized the antipseudomonal activities of imipenem and meropenem, they had no effect on the activity of BMS-181139. These results suggest that the uptake of BMS-181139 into pseudomonal cells occurs by a non-D2 pathway. Compared with imipenem and meropenem, BMS- 181139 may have a slightly higher affinity for penicillin-binding protein 2 (PBP-2) of P. aeruginosa. The rates of resistance development to imipenem, meropenem, and BMS-181139 in P. aeruginosa strains were similar; resistance occurred at frequencies of approximately 10(-7) to 10(-8). Resistance to BMS-181139 in P. aeruginosa is presumed to be caused by its diminished permeability since no change in their penicillin-binding protein affinities or beta-lactamase levels could be detected. In summary, BMS-181139 is a new carbapenem which differs from other known carbapenems in its lack of cross-resistance with imipenem. This difference could be explained by the permeation of BMS-181139 through a non-D2 channel, compared to the preferential uptake of other carbapenems by the D2 porin.

This article has been cited by other articles:

• Köhler, T., Michea-Hamzehpour, M., Epp, S. F., Pechere, J.-C. (1999). Carbapenem Activities against Pseudomonas aeruginosa: Respective Contributions of OprD and Efflux Systems. Antimicrob. Agents Chemother. 43: 424-427 [Abstract] [Full Text]